- Home
- App-Analyse
- Anticoagulation Manager
- Anticoagulation Manager Vs. AnticoagEvaluator
Anticoagulation Manager im Vergleich zu AnticoagEvaluator Nutzung und Statistiken
The Anticoagulation Manager is a mobile application developed through the collaborative efforts of the CDC and the Georgia Institute of Technology. Since the determination of the correct type and dose of anticoagulant drugs can be challenging, this application is a resource for clinicians to appropriately order laboratory testing and choose anticoagulant drugs for the various indications. It gives clinicians evidence-based, accessible, and accurate information when prescribing anticoagulants to prevent and/or treat abnormal clotting states.
- Apple App Store
- Kostenlos
- Medizin
Rang speichern
- -
Make well-informed decisions on antithrombotic therapy for your non-valvular AF patients with the updated AnticoagEvaluator.
Use the app to:
• Calculate a patient's renal function and risk of ischemic stroke, thromboembolism, and bleed
• Review ACC/AHA/HRS Guideline-driven therapy guidance for stroke prevention
• Generate individualized risk for antithrombotic therapy options based on individual clinical trials.
• Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics.
This app is based on SPARC Tool, developed by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at www.sparctool.com
- Apple App Store
- Kostenlos
- Medizin
Rang speichern
- -
Anticoagulation Managervs. AnticoagEvaluator Ranking-Vergleich
Vergleichen Sie Anticoagulation Manager den Ranking-Trend der letzten 28 Tage mit AnticoagEvaluator
Rang
Keine Daten verfügbar
Anticoagulation Manager im Vergleich zu AnticoagEvaluator Ranking im Ländervergleich
Vergleichen Sie Anticoagulation Manager den Ranking-Trend der letzten 28 Tage mit AnticoagEvaluator
Keine Daten zum Anzeigen
Stellen Sie mit unserer kostenlosen Testversion Vergleiche mit jeder Website an
Anticoagulation Manager VS.
AnticoagEvaluator
Dezember 23, 2024